Sara Sofia De Lucia

Dr. Sara Sofia De Lucia

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
STSchepis Tommaso
Schepis Tommaso
SLSara Sofia De Lucia
Sara Sofia De Lucia
ENEnrico Celestino Nista
Enrico Celestino Nista
VMVittoria Manilla
Vittoria Manilla
GPGiulia Pignataro
Giulia Pignataro
Marcello CandelliMarcello Candelli
Marcello Candelli
The gut microbiota is a critical element in the balance between human health and disease. Its impairment, defined as dysbiosis, is associated with gastroenterological and systemic diseases. Pancreatic secretions are involved in the composition and changes of the gut microbiota, and the gut microbiota may colonize the pancreatic parenchyma and be associated with the occurrence of diseases. The gut microbiota and the pancreas influence each other, resulting in a “gut microbiota-pancreas axis”. Moreover, the gut microbiota may be involved in pancreatic diseases, both through direct bacterial colonization and an indirect effect of small molecules and toxins derived from dysbiosis. Pancreatic diseases such as acute pancreatitis, chronic pancreatitis, autoimmune pancreatitis, and pancreatic cancer are common gastroenterological diseases associated with high morbidity and mortality. The involvement of the microbiota in pancreatic diseases is increasingly recognized. Therefore, modifying the intestinal bacterial flora could have important therapeutic implications on these pathologies. The aim of this study is to review the literature to evaluate the alterations of the gut microbiota in pancreatic diseases, and the role of the microbiota in the treatment of these diseases.

Verified
Journal Article
Open access
PDF file
ENEnrico Celestino Nista
Enrico Celestino Nista
SLSara Sofia De Lucia
Sara Sofia De Lucia
VMVittoria Manilla
Vittoria Manilla
STSchepis Tommaso
Schepis Tommaso
APAntonio Pellegrino
Antonio Pellegrino
Marcello CandelliMarcello Candelli
Marcello Candelli
Autoimmune pancreatitis (AIP) is a rare disease. The diagnosis of AIP is difficult and should be made by a comprehensive evaluation of clinical, radiological, serological, and pathological findings. Two different types of AIP have been identified: autoimmune pancreatitis type 1 (AIP-1), which is considered a pancreatic manifestation of multiorgan disease related to IgG4, and autoimmune pancreatitis type 2 (AIP-2), which is considered a pancreas-specific disease not related to IgG4. Although the pathophysiological conditions seem to differ between type 1 and type 2 pancreatitis, both respond well to steroid medications. In this review, we focused on the pathogenesis of the disease to develop a tool that could facilitate diagnosis and lead to the discovery of new therapeutic strategies to combat autoimmune pancreatitis and its relapses. The standard therapy for AIP is oral administration of corticosteroids. Rituximab (RTX) has also been proposed for induction of remission and maintenance therapy in relapsing AIP-1. In selected patients, immunomodulators such as azathioprine are used to maintain remission. The strength of this review, compared with previous studies, is that it focuses on the clear difference between the two types of autoimmune pancreatitis with a clearly delineated and separate pathogenesis. In addition, the review also considers various therapeutic options, including biologic drugs, such as anti-tumor necrosis factor (TNF) therapy, a well-tolerated and effective second-line therapy for AIP type 2 relapses or steroid dependence. Other biologic therapies are also being explored that could provide a useful therapeutic alternative to corticosteroids and immunosuppressants, which are poorly tolerated due to significant side effects.

18 April 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
SLSara Sofia De Lucia
Sara Sofia De Lucia
Marcello CandelliMarcello Candelli
Marcello Candelli
Giorgia PolitoGiorgia Polito
Giorgia Polito
RMRossella Maresca
Rossella Maresca
TMTeresa Mezza
Teresa Mezza
ENEnrico Celestino Nista
Enrico Celestino Nista
The nutritional management of acute pancreatitis (AP) patients has widely changed over time. The “pancreatic rest” was the cornerstone of the old paradigm, and nutritional support was not even included in AP management. Traditional management of AP was based on intestinal rest, with or without complete parenteral feeding. Recently, evidence-based data underlined the superiority of early oral or enteral feeding with significantly decreased multiple-organ failure, systemic infections, surgery need, and mortality rate. Despite the current recommendations, experts still debate the best route for enteral nutritional support and the best enteral formula. The aim of this work is to collect and analyze evidence over the nutritional aspects of AP management to investigate its impact. Moreover, the role of immunonutrition and probiotics in modulating inflammatory response and gut dysbiosis during AP was extensively studied. However, we have no significant data for their use in clinical practice. This is the first work to move beyond the mere opposition between the old and the new paradigm, including an analysis of several topics still under debate in order to provide a comprehensive overview of nutritional management of AP.

21 October 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
ENEnrico Celestino Nista
Enrico Celestino Nista
APAntonio Pellegrino
Antonio Pellegrino
LGLucia Giuli
Lucia Giuli
Marcello CandelliMarcello Candelli
Marcello Candelli
STSchepis Tommaso
Schepis Tommaso
Antonio GasbarriniAntonio Gasbarrini
Antonio Gasbarrini
Helicobacter pylori (H. pylori) resistance to antibiotics has increased worldwide in recent decades, especially to clarithromycin. As a result, the World Health Organization (WHO) identified clarithromycin-resistant H. pylori as a “high priority” pathogen in 2017. As international guidelines recommend empirical therapy as first-line treatment, it is crucial to know local resistance rates and history of antibiotic use to determine the most appropriate first-line antibiotic treatment. Italy is one of the European countries with the highest prevalence of H. pylori infection and the highest percentage of antibiotic-resistant H. pylori. The aim of this review is to summarize all data on H. pylori antibiotic resistance in Italy in order to quantify the current rate and determine the most effective therapeutic approach. The study confirms an elevated level of resistance to clarithromycin, metronidazole, and levofloxacin in Italy. In addition, our results show a satisfactory eradication rate for a bismuth-based regimen when used as first- or second-line treatment. Naive patients are also successfully treated with clarithromycin-based quadruple therapies. Considering the good results of bismuth-based therapy as recovery therapy, this argues for the potential use of clarithromycin quadruple therapy as a first-line treatment.

Verified
Journal Article
Open access
PDF file
ENEnrico Celestino Nista
Enrico Celestino Nista
Simone ParelloSimone Parello
Simone Parello
MBMattia Brigida
Mattia Brigida
GAGiulio Amadei
Giulio Amadei
ASAngela Saviano
Angela Saviano
Veronica OjettiVeronica Ojetti
Veronica Ojetti
Acute pancreatitis (AP) is a common and potentially severe gastrointestinal condition characterized by acute inflammation of the pancreas. The pathophysiology of AP is multifactorial and intricate, involving a cascade of events that lead to pancreatic injury and systemic inflammation. The progression of AP is influenced by many factors, including genetic predispositions, environmental triggers, and immune dysregulation. Recent studies showed a critical involvement of the gut microbiota in shaping the immune response and modulating inflammatory processes during AP. This review aims to provide a comprehensive overview of the emerging role of gut microbiota and probiotics in AP. We analyzed the implication of gut microbiota in pathogenesis of AP and the modification during an acute attack. The primary goals of microbiome-based therapies, which include probiotics, prebiotics, antibiotics, fecal microbiota transplantation, and enteral nutrition, are to alter the composition of the gut microbial community and the amount of metabolites derived from the microbiota. By resetting the entire flora or supplementing it with certain beneficial organisms and their byproducts, these therapeutic approaches aim to eradicate harmful microorganisms, reducing inflammation and avoiding bacterial translocation and the potential microbiota-based therapeutic target for AP from nutrition to pre- and probiotic supplementation to fecal transplantation.

29 September 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
SLSara Sofia De Lucia
Sara Sofia De Lucia
GCGea Ciccarelli
Gea Ciccarelli
GGGiulia Gliozzo
Giulia Gliozzo
GGGianfranco Di Giuseppe
Gianfranco Di Giuseppe
LSLaura Soldovieri
Laura Soldovieri
TMTeresa Mezza
Teresa Mezza
Context: Fatty pancreas is associated with obesity and metabolic alterations and may coexist with pancreatic structural remodeling. However, its contribution to β-cell dysfunction remains unclear. Objective: We investigated the relationship between pancreatic fat, tissue remodeling, and β-cell function. Design: We conducted a cross-sectional study in individuals with ultrasound-detected pancreatic hyperechogenicity without prior diagnosis of diabetes. Pancreatic fat was quantified by magnetic resonance imaging (MRI)-derived proton density fat fraction, while tissue stiffness was assessed by shear wave elastography. Metabolic phenotyping was based on oral glucose tolerance test (OGTT). Participants: We recruited 29 individuals with ultrasound-detected fatty pancreas (F/M 16/13, age 54 ± 10.4 years) and assessed glucose tolerance with OGTT: 75.9% exhibited normal glucose tolerance (n = 22), while 24.1% had impaired glucose tolerance (n = 7). Results: MRI-derived pancreatic fat fraction was positively correlated with anthropometric measures (body mass index ρ = 0.43, P = .02) and β-cell function (β-cell glucose sensitivity ρ = 0.40, P = .03). Pancreatic stiffness correlated negatively with body weight (ρ = −0.38, P = .04), did not correlate with pancreatic fat fraction (ρ = −0.15, P = .44), and was correlated inversely with the potentiation factor ratio 1 (ρ = −0.44, P = .02), a measure of non–glucose-dependent amplification of insulin secretion. Conclusion: Intrapancreatic fat and pancreatic stiffness appear to reflect distinct pathophysiological processes, with potentially different relationships to systemic metabolic status and β-cell function. These findings support a more nuanced view of pancreatic structural alterations as heterogeneous markers of metabolic dysfunction.